Dr. Shelton A. Viola

Hematology | Oncology
Naval Medical Center
620 John Paul Jones Cir, 
Portsmouth, VA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Naval Medical Center
620 John Paul Jones Cir, 
Portsmouth, VA 

Overview

Shelton Viola is a Hematologist and an Oncologist practicing medicine in Portsmouth, Virginia.

His clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Ganglioneuroblastoma, and Febrile Neutropenia.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 14 clinical trials. Dr. Viola is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Naval Medical Center
620 John Paul Jones Cir, Portsmouth, VA 23708

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
View 8 Less Clinical Trials

6 Total Publications

Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.
Journal: Blood advances
Published: July 22, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Lloyd A. Shabazz
Hematology | Oncology
Expertise in
29
conditions
Dr. Lloyd A. Shabazz
Hematology | Oncology
Referral may be required

Bon Secours Maryview Outpatient Infusion

355 Crawford St Ste 300, 
Portsmouth, VA 
 (1.4 miles away)
757-396-6333
Languages Spoken:
English
See accepted insurances

Lloyd Shabazz is a Hematologist and an Oncologist practicing medicine in Portsmouth, Virginia. Dr. Shabazz is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Inflammatory Breast Cancer, and Sickle Cell Disease.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mrinal Patnaik is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Patnaik is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Patnaik is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Animesh Pardanani is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Pardanani is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Systemic Mastocytosis, Essential Thrombocythemia, Splenectomy, and Bone Marrow Aspiration. Dr. Pardanani is currently accepting new patients.

Frequently Asked Questions about Dr. Shelton A. Viola

How do I make an appointment with Dr. Shelton A. Viola?

You can book an appointment with Dr. Shelton A. Viola by calling their office at 757-953-4529. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shelton A. Viola a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shelton A. Viola is classified as an Experienced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shelton A. Viola specialize in?

While Dr. Shelton A. Viola is a Hematology, they have specific expertise in Leukemia, Acute Myeloid Leukemia (AML), and Ganglioneuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Shelton A. Viola participate in research or clinical trials?

Yes. Dr. Shelton A. Viola has published 6 articles and abstracts on conditions like Leukemia. You can view a list of Dr. Shelton A. Viola's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shelton A. Viola accept my insurance?

Dr. Shelton A. Viola accepts most major insurance plans, including Cigna and HealthKeepers. We recommend calling the office directly at 757-953-4529 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Viola's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile